{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:36:58Z","timestamp":1789983418421,"version":"4.0.1"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Amyloidosis refers to a group of conditions where abnormal protein\u2014or amyloid\u2014deposits in tissues or organs, often leading to organ malfunction. Amyloidosis affects nearly any organ system, but especially the heart, kidneys, liver, peripheral nervous system, and gastrointestinal tract. Neuromuscular deficits comprise some of its ubiquitous manifestations. Amyloidosis can be quite challenging to diagnose given its clinical heterogeneity and multi-system nature. Early diagnosis with accurate genetic and serologic subtyping is key for effective management and prevention of organ decline. In this review, we highlight the value of a multidisciplinary comprehensive amyloidosis clinic. While such a model exists at numerous clinical and research centers across the globe, the lack of more widespread adoption of such a model remains a major hindrance to the timely diagnosis of amyloidosis. Such a multidisciplinary care model allows for the timely and effective diagnosis of amyloidosis, be it acquired amyloid light amyloidosis (AL), hereditary transthyretin amyloidosis (hATTR), or wild type amyloidosis (TTR-wt), especially in the current era of personalized genomic medicine. A multidisciplinary clinic optimizes the delivery of singular or combinatorial drug therapies, depending on amyloid type, fibril deposition location, and disease progression. Such an arrangement also helps advance research in the field. We present our experience at The Ohio State University, as one example out of many, to highlight the centrality of a multi-disciplinary clinic in amyloidosis care.<\/jats:p>","DOI":"10.3389\/fneur.2022.935936","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T10:25:36Z","timestamp":1666175136000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Multidisciplinary amyloidosis care in the era of personalized medicine"],"prefix":"10.3389","volume":"13","author":[{"given":"Naresh","family":"Bumma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Kahwash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir V.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Isfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Freimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Vallakati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse","family":"Redder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney M.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Efebera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro","family":"Stino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"B1","first-page":"EY3F","article-title":"Heart transplantation in AL amyloidosis","volume":"115","author":"Dahlberg","year":"2018","journal-title":"Lakartidningen"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/1831202a0","article-title":"Calkins EJN. Electron microscopic observations on a fibrous component in amyloid of diverse origins","volume":"183","author":"Cohen","year":"1959","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1182\/blood-2009-04-202879","article-title":"How I treat amyloidosis","volume":"114","author":"Comenzo","year":"2009","journal-title":"Blood"},{"key":"B4","volume-title":"Multiple Myeloma I. The Pathogenesis of Amyloidosis","author":"Osserman","year":"1964"},{"key":"B5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1046\/j.1365-2796.2003.01262.x","article-title":"Westermark PJJoim. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies","volume":"255","author":"Merlini","year":"2004","journal-title":"J Intern Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000506617","article-title":"When to suspect a diagnosis of amyloidosis","volume":"143","author":"Vaxman","year":"2020","journal-title":"Acta Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"iv63","DOI":"10.1093\/annonc\/mdn200","article-title":"Amyloidosis: is a cure possible?","volume":"19","author":"Merlini","year":"2008","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood."},{"key":"B9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1182\/blood-2012-03-413682","article-title":"Sethi SJB. How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Liedtke MJB. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/bjh.15455","article-title":"et al. Daratumumab proves safe and highly effective in AL amyloidosis","volume":"185","author":"Khouri","year":"2019","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"8003","DOI":"10.1200\/JCO.2021.39.15_suppl.8003","article-title":"Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study","volume":"39","author":"Kastritis","year":"2021","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2020-139323","article-title":"Cael-101 is well-tolerated in AL amyloidosis patients receiving concomitant cyclophosphamide-bortezomib-dexamethasone (CyborD): a phase 2 dose-finding study (NCT04304144)","volume":"136","author":"Valent","year":"2020","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8076","article-title":"Birtamimab in patients with Mayo stage IV AL amyloidosis: rationale for confirmatory affirm-AL phase 3 study","author":"Gertz","year":"2022","journal-title":"Am Soc Clin Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"P7","DOI":"10.1186\/1750-1172-10-S1-P7","article-title":"Monia BPJOjord","volume":"10","author":"Benson","year":"2015"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11886-017-0911-5","article-title":"Transthyretin cardiac amyloidosis","volume":"19","author":"Mankad","year":"2017","journal-title":"Curr Cardiol Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"129453","DOI":"10.1016\/j.bbagen.2019.129453","article-title":"S-Homocysteinylation effects on transthyretin: worsening of cardiomyopathy onset","volume":"1864","author":"Leri","year":"2020","journal-title":"Biochim Biophys Acta Gen Subj."},{"key":"B25","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.radcr.2018.06.012","article-title":"Technetium-99m pyrophosphate cardiac SPECT in endomyocardial biopsy negative cardiac amyloidosis","volume":"13","author":"Krupa","year":"2018","journal-title":"Radiol Case Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA."},{"key":"B30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR cardiac amyloidosis","volume":"18","author":"Casta\u00f1o","year":"2012","journal-title":"Congest Heart Fail."},{"key":"B31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"Neurodegener Dis Manag"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"23","author":"Adams","year":"2022","journal-title":"Amyloid"},{"key":"B33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"Methods Mol Biol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jnutbio.2015.12.009","article-title":"The polyphenol Oleuropein aglycone hinders the growth of toxic transthyretin amyloid assemblies","volume":"30","author":"Leri","year":"2016","journal-title":"J Nutr Biochem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00392-012-0463-z","article-title":"Green tea halts progression of cardiac transthyretin amyloidosis: an observational report","volume":"101","author":"Kristen","year":"2012","journal-title":"Clin Res Cardiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"718188","DOI":"10.3389\/fnins.2021.718188","article-title":"Green tea polyphenol epigallocatechin-gallate in amyloid aggregation and neurodegenerative diseases","volume":"15","author":"Fernandes","year":"2021","journal-title":"Front Neurosci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.bbagen.2018.03.023","article-title":"Oleuropein aglycone: a polyphenol with different targets against amyloid toxicity","volume":"1862","author":"Leri","year":"2018","journal-title":"Biochim Biophys Acta Gen Subj."},{"key":"B38","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3389\/fphar.2019.00305","article-title":"Antisense oligonucleotide: basic concepts and therapeutic application in inflammatory bowel disease","volume":"10","author":"Di Fusco","year":"2019","journal-title":"Front Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000427","article-title":"Wild type transthyretin amyloid cardiomyopathy. The Gordian-knot of novel therapeutic regimens","author":"Zegkos","year":"2021","journal-title":"Cardiol Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.34067\/KID.0004922020","article-title":"Beta-2 microglobulin amyloidosis: past, present, and future","volume":"360","author":"Portales-Castillo","year":"2020","journal-title":"Kidney."},{"key":"B41","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13018-017-0697-6","article-title":"The unresolved problem of beta-2 microglobulin amyloid deposits in the intervertebral discs of long-term dialysis patients","volume":"12","author":"Tsai","year":"2017","journal-title":"J Orthop Surg Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e1002532","DOI":"10.1371\/journal.pmed.1002532","article-title":"Cost-effectiveness of multidisciplinary care in mild to moderate chronic kidney disease in the United States: a modeling study","volume":"15","author":"Lin","year":"2018","journal-title":"PLoS Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/j.1524-4733.2010.00797.x","article-title":"Cost-effectiveness of specialized multidisciplinary heart failure clinics in Ontario, Canada","volume":"13","author":"Wijeysundera","year":"2010","journal-title":"Value Health."},{"key":"B44","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/AJP.0000000000001009","article-title":"Cost-effectiveness of multidisciplinary interventions for chronic low back pain: a narrative review","volume":"38","author":"Chowdhury","year":"2021","journal-title":"Clin J Pain."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/jnnp.74.9.1258","article-title":"Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000","volume":"74","author":"Traynor","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B46","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0953-6205(03)00076-1","article-title":"Sarcoidosis: benefits of a multidisciplinary approach","volume":"14","author":"Drent","year":"2003","journal-title":"Eur J Intern Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3390\/jcm9020390","article-title":"Comprehensive care for patients with sarcoidosis","volume":"9","author":"Moor","year":"2020","journal-title":"J Clin Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11899-021-00646-0","article-title":"Multidisciplinary approach to older adults with hematologic malignancies\u2014a paradigm shift","volume":"17","author":"Wall","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"key":"B49","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40271-017-0273-5","article-title":"Light chain (AL) amyloidosis: the journey to diagnosis","volume":"11","author":"McCausland","year":"2018","journal-title":"Patient"},{"key":"B50","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.healun.2016.03.004","article-title":"Analysis of diagnostic and therapeutic strategies in advanced cardiac light-chain amyloidosis","volume":"35","author":"Sayago","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"B51","doi-asserted-by":"publisher","first-page":"S160","DOI":"10.1016\/j.bbmt.2013.12.255","article-title":"A multidisciplinary team approach for diagnosis and treatment of patients with AL amyloidosis","volume":"20","author":"Finn","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e13296","DOI":"10.1111\/eci.13296","article-title":"Multidisciplinary approach in the management of hATTR","volume":"50","author":"Losada","year":"2020","journal-title":"Eur J Clin Invest."},{"key":"B53","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.cardfail.2014.06.192","article-title":"The amyloid challenge: a multidisciplinary approach to avoid readmissions, promote self-care, and maintain optimal quality of life","volume":"20","author":"Almansa","year":"2014","journal-title":"J Cardiac Failure"},{"key":"B54","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/jamasurg.2017.5080","article-title":"Carpten JJJs. Integrating the genetics of race and ethnicity into cancer research: trailing jane and john Q public","volume":"153","author":"Newman","year":"2018","journal-title":"JAMA Surg"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.935936\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T10:25:43Z","timestamp":1666175143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.935936\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":54,"alternative-id":["10.3389\/fneur.2022.935936"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.935936","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,13]]},"article-number":"935936"}}